Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

12.8%

52 terminated/withdrawn out of 407 trials

Success Rate

81.9%

-4.7% vs industry average

Late-Stage Pipeline

24%

98 trials in Phase 3/4

Results Transparency

24%

56 of 235 completed trials have results

Key Signals

27 recruiting56 with results48 terminated4 withdrawn

Enrollment Performance

Analytics

Phase 2

152(44.6%)

Phase 3

63(18.5%)

N/A

52(15.2%)

Phase 1

36(10.6%)

Phase 4

35(10.3%)

Early Phase 1

3(0.9%)

341Total

Phase 2(152)

Phase 3(63)

N/A(52)

Phase 1(36)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (407)

Showing 20 of 407 trials

NCT05525858Active Not Recruiting

KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II

Role: collaborator

NCT00144976Not ApplicableCompleted

Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma

Role: collaborator

NCT02436707Phase 2Active Not Recruiting

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Role: collaborator

NCT04808245Phase 1Active Not Recruiting

A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas

Role: collaborator

NCT02558816Phase 1Completed

A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients

Role: collaborator

NCT05300282Phase 1Active Not Recruiting

Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients

Role: collaborator

NCT05306041Phase 2Recruiting

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer

Role: collaborator

NCT04611867Not ApplicableRecruiting

Study of PRO in Patients With Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay)

Role: collaborator

NCT06068985Phase 2Active Not Recruiting

Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade

Role: collaborator

NCT04947605Active Not Recruiting

Epidemiological Landscape of Cervical Cancer in Latin America

Role: collaborator

NCT04292574Recruiting

UK SMA Patient Registry

Role: collaborator

NCT03654833Phase 2Completed

Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma

Role: collaborator

NCT07336134Not ApplicableRecruiting

PopSci CHW4CervixHealth

Role: collaborator

NCT05050214Phase 2Completed

Obinutuzumab in Primary MN

Role: collaborator

NCT03455582Not ApplicableCompleted

Cognition Evolution and MRI Markers in PPMS Patients on 2 Years

Role: collaborator

NCT04245085Phase 2Completed

ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma

Role: collaborator

NCT03915678Phase 2Active Not Recruiting

Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

Role: collaborator

NCT06225505Not ApplicableRecruiting

Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)

Role: collaborator

NCT05911178Not ApplicableActive Not Recruiting

Impact of Microglial Activation on Synaptic Density in Alzheimer's Disease

Role: collaborator

NCT04487756Phase 1Completed

Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer

Role: collaborator